Showing 3841-3850 of 5015 results for "".
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Metabolomic Signature Predictive of Ocular Side Effects in Dupilumab-Treated AD: Studyhttps://practicaldermatology.com/news/metabolomic-signature-may-predict-ocular-side-effects-in-dupilumab-treated-atopic-dermatitis-study/2474199/New research suggests baseline metabolic differences may help predict which patients with atopic dermatitis (AD) are most likely to develop ocular complications from dupilumab. In findings published in
- Kenvue’s Ricciardone Explains New Data on the Value of Teamwork in Moisturizers and Retinoidshttps://practicaldermatology.com/news/Kenvues-Ricciardone-Explains-New-Data-Value-Teamwork-Moisturizers-Retinoids/2474166/Data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, supported the “full sandwich” moisturizer method for new retinoid users who may experience sensitivity from retinization during the skin acclimation period while also suggesting that Neutrogena® H
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://practicaldermatology.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- Almirall Hosts 16th Skin Academyhttps://practicaldermatology.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Emrosi Officially Launched for Treatment of Inflammatory Rosaceahttps://practicaldermatology.com/news/emrosi-officially-launched-for-treatment-of-inflammatory-rosacea/2471775/Journey Medical has announced the launch and initial prescriptions for Emrosi for the treatment of inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, the minocycline hydrochloride modi
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea